Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Parallel Health Inc. manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current prosecution is localized within a single technical and administrative path. For a practitioner, this means that the prosecution strategy is highly dependent on the individual examiner's technical perspective on biotechnology and pharmaceutical standards.
GRIZER, CASSANDRA SENN is the busiest examiner, overseeing 1 pending office action. The presence of 1 distinct examiner and 1 distinct art unit shows that the biotechnology filings are currently being reviewed by one specific individual in one specialized unit. This centralized review process allows the practitioner to focus their efforts on one set of art unit guidelines. However, it also means that there is no opportunity to leverage different examiner perspectives within the current pending workload, making the relationship with this specific examiner paramount for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 75.0% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18466675 | MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS | GRIZER, CASSANDRA SENN | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18466675 | MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS | GRIZER, CASSANDRA SENN | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18466675 | MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 5d overdue | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial